secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001213900-25-039903
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q1 2025 net revenue $39.1M, net income $20.6M vs loss; raises H1 guidance to high-end
--------------------------------------------------------------------------------

- Q1 net revenue $39.1M; net income $20.6M ($0.32 EPS) vs net loss of $14.5M ($0.25 loss) in Q1 2024.
- Adjusted EBITDA $23.6M; cash from operations $19.7M; cash and short-term investments $77.5M at March 31.
- Expects to be at high-end of H1 2025 net sales guidance of $62M-$70M based on current order trends.
- Inpatient sales team fully staffed; DefenCath inpatient shipments doubled in last 3 months; Phase 3 TPN-CLABSI study started.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/0001213900-25-039903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/ea0240827-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-039903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer